



Benefits Investigation and Prescription Form

Remicade Infliximab Simponi golimumal

Complete and fax this Form to 855-224-5072 or mail to 2250 Perimeter Park Drive, Suite 300, Morrisville, NC 27560. For assistance, call 877-CarePath (877-227-3728), Monday–Friday, 8:00 AM–8:00 PM, ET

Janssen CarePath cannot accept any information without an executed Business Associate Agreement or Patient Authorization Form, which can be found at <u>JanssenCarePath.com</u> or as the last two pages of this document.

The information you provide will be used by Janssen Biotech, Inc., our affiliates, and our service providers for your patient's enrollment and participation in Janssen CarePath.

Our **Privacy Policy** governs the use of the information you provide. By submitting this form, you indicate that you read, understand, and agree to these terms.

1. PATIENT INFORMATION (REQUIRED)	6. PRESCRIPTION INFORMATION: Rx: SIMPONI® (If requesting benefits investigation only, do not complete this section. The prescription is only valid if received by fax. If not faxed, prescription must be submitted on state-specific blank, if applicable for your state)
NAME (First, MI, Last)SEX \(\subseteq M \subseteq F \)	DIRECTIONS: STARTER DOSES
DOB (MM/DD/YYYY)ADDRESS	STARTER DUSES 200 mg at Week 0; 2 single-use autoinjectors, 100 mg/1.0 mL SC 100 mg at Week 2; 1 single-use autoinjector, 100 mg/1.0 mL SC
CITYSTATEZIP CODEE-MAIL	200 mig at Week 0, 2 single-use autoinjectors, 100 mig/1.0 mL SC 100 mg at Week 2; 1 single-use prefilled syringes, 100 mg/1.0 mL SC 100 mg at Week 2; 1 single-use prefilled syringe, 100 mg/1.0 mL SC
CELL PHONEHOME PHONEWORK PHONEPREFERRED NUMBER TO CALL Cell home work BEST TIME TO CONTACT moming afternoon evening	MAINTENANCE THERAPY MAINTENANCE THERAPY
· · · · · · · · · · · · · · · · · · ·	☐ 1 single-use autoinjector, 100 mg/1.0 mL SC every 4 weeks ☐ 1 single-use prefilled syringe, 100 mg/1.0 mL SC every 4 weeks Refills #
2. INSURANCE INFORMATION (REQUIRED. Include alpha prefix and suffix with policy and group# when applicable or provide a copy of insurance cards)	OTHER T single-use autoingector, foo mg/1.0 mic so every 4 weeks T single-use prefilled syninge, foo mg/1.0 mic so every 4 weeks hellis #
PRIMARY INSURANCE CARDHOLDER	■ PRESCRIBER SIGNATURE (NO STAMPS ALLOWED) REQUIRED TO VALIDATE PRESCRIPTION: I certify that therapy with SIMPONI®
RELATIONSHIP TO CARDHOLDER EMPLOYER INS. CO. PHONE	is medically necessary for this patient. I will be supervising the patient's treatment accordingly, and I have reviewed the current SIMPONI® Prescribing
POLICY # GROUP #	Information. I authorize Janssen CarePath to act on my behalf for the limited purposes of transmitting this prescription to the appropriate pharmacy designated by me, the patient, or the patient's plan.
SECONDARY INSURANCE CARDHOLDER	
RELATIONSHIP TO CARDHOLDER EMPLOYER INS. CO. PHONE	PRESCRIBER SIGNATURE (Dispense as Written) DATE
POLICY # GROUP #	SUPERVISING PHYSICIAN SIGNATURE (if applicable) DATE
PRESCRIPTION DRUG INSURER CARD/BIN # PHONE	SUPERVISING PHYSICIAN NAME
Is patient a dependent of the insured (child <18 yrs; student >18 yrs)? Check if yes.	7. REMICADE® or Infliximab PREFERRED SITE OF INFUSION (REQUIRED)
PLEASE INVESTIGATE OUT-OF-NETWORK BENEFITS FOR REMICADE® or Infliximab	(Fields below do not need to be completed if information is the same as in the Prescriber Information section)
NOTE: For SIMPONI®, pharmacy benefit will be investigated. If patient does not have a pharmacy benefit, medical benefits will be investigated.	Prescribing MD's office Non-prescribing MD's office Hospital outpatient Home infusion/Infusion Provider Company Other
3. PRIOR MEDICATIONS (REQUIRED. Specify—P=Prior, C=Current, F=Failure)	PHYSICIAN OR INFUSION PROVIDER NAME
□ 5-ASA □ Azathioprine □ Cimzia® □ Cyclosporine □ Methotrexate	PRACTICE/FACILITY NAME
G-MP Azulfidine® Corticosteroids Humira® Other	ADDRESS
	CITYSTATEZIP CODE
4. PRESCRIBER INFORMATION (REQUIRED)	PHONEFAXCONTACT NAME
PRESCRIBER NAME (First, Last)	INSURANCE PROVIDER #TAX ID #
SPECIALTY OFFICE CONTACT	8. SHIPPING INFORMATION FOR SIMPONI® (REQUIRED to complete benefits investigation even if not prescribing. NOTE: Shipments cannot be sent
ADDRESS OFFICE CONTACT	to P.O. Boxes)
CITYSTATEZIP CODE	SHIP TO: PROVIDER OFFICE—Initial injection only
E-MAIL PHONE FAX	PATIENT'S HOME—I have instructed the patient in proper injection technique for SIMPONI® and the patient will self-administer 🗖 OTHER
MEDICAID/MEDICARE PROVIDER # TAX ID #	NAME (if different than above)
STATE LICENSE # UPIN/NPI #	ADDRESS CITY STATE
Are you the prescribing specialist? (Required) YES NO: IF NO, REFERRING SPECIALIST	ZIP CODEPHONEFAX
REFERRING PHYSICIAN SPECIALTY	9. PREFERRED SPECIALTY PHARMACY (Provider to check one below)
5. CLINICAL INFORMATION (REQUIRED. Visit JanssenCarePath.com for ICD-10 codes or consult the ICD-10 code book for additional information)	As the treating physician, I have discussed preference for a Specialty Pharmacy (SP) with this patient. This patient prefers use of the SP indicated below. I authorize
REMICADE® or 🗖 Infliximab—DIAGNOSIS: Crohn's Disease, Fistula (Secondary to Crohn's Disease), Ulcerative Colitis	Janssen Biotech, Inc., and its representatives to fax this prescription to: 1. The SP designated as checked below, provided it is approved by this patient's plan. 2. If the SP designated is not a plan-approved SP, then to a SP approved by this patient's plan. 3. If there is no preferred SP indicated, then to any SP approved by this patient's plan.
DIAGNOSIS CODE INDICATION	Accredo Amber BioPlus Optum CVS Caremark Cigna Diplomat Humana
DOSAGE/FREQUENCY NUMBER OF PRIOR REMICADE® OR Infliximab INFUSIONS unknown 0 3 4+	□ Kroger □ Senderra □ AllianceRx □ Other
# OF VIALS TO BE USED ANTICIPATED # OF INFUSIONS	10. PRIOR AUTHORIZATION (Please check the appropriate box[es] below to request assistance with prior authorizations)
□ SIMPONI®—DIAGNOSIS: Ulcerative Colitis	Prior Authorization Form Assistance By checking this box, I request that Janssen CarePath assist my office in providing the requirements of this patient's
DIAGNOSIS CODE INDICATION	health plan related to prior authorization for treatment with REMICADE® or Infliximab. I understand that assistance includes obtaining the health plan-specific prior
■ ADDITIONAL CLINICAL INFORMATION	authorization Form, and providing it based upon the patient-specific information provided on this Form. I understand that the partially completed prior authorization Form will be provided to my office by Janssen CarePath for possible completion and submission in the office's sole discretion.
DATE OF DIAGNOSIS OR YEARS WITH DISEASEPATIENT WEIGHT Ibkg.	Prior Authorization Status Monitoring By checking this box, I request that Janssen CarePath actively monitor the status of the prior authorization submission.
PREVIOUS TB TEST (DATE) HEPATITIS B VIRUS TEST (DATE) SCHEDULED DATE OF INFUSION	I request that Janssen CarePath provide status updates to my office with respect to this patient's prior authorization for treatment with the specified medication.

Please see the full Prescribing Information, including Boxed Warning, and Medication Guides for <u>SIMPONI</u>®, <u>REMICADE</u>®, and <u>Infliximab</u>. Provide the appropriate Medication Guide to your patients and encourage discussion.

Information about your patient's insurance coverage, cost support options, and treatment support is given by service providers for Janssen CarePath. The information you get does not require you or your patient to use any Janssen product. Because the information we give you comes from outside sources, Janssen CarePath cannot promise the information will be complete. Janssen CarePath is not for patients in the Johnson & Johnson Patient Assistance Foundation.



Janssen Patient Support Program Patient Authorization Form

Patients should read the Patient Authorization, check the desired permission boxes, and return both pages of the Form to Janssen Patient Support Program.

- Download a copy, print, check the desired boxes, and sign. Your healthcare provider may scan the completed Form and upload on Provider Portal, or completed Form may be faxed to 855-224-5072 or mailed to Janssen CarePath, 2250 Perimeter Park Drive, Suite 300, Morrisville, NC 27560
- You may be able to eSign a digital Form in your healthcare provider's office or on the Janssen CarePath Patient Account at MyJanssenCarePath.com

Patient Name:	Email Address:

I give permission for each of my "Healthcare Providers" (eg, my physicians, pharmacists, specialty pharmacies, other healthcare providers, and their staff) and "Insurers" (eg, my health insurance plans) to share my Protected Health Information as described on this Form.

My "Protected Health Information" includes any and all information related to my medical condition, treatment, prescriptions, and health insurance coverage. The following person(s) or class of person(s) are given permission to receive and use my Protected Health Information (collectively "Janssen"):

- Johnson & Johnson Health Care Systems Inc., its affiliated companies, agents, and representatives
- Providers of other sources of funding, including foundations and co-pay assistance providers
- Service providers for the patient support programs, including subcontractors or Healthcare Providers helping Janssen run the programs
- Service providers maintaining, transmitting, de-identifying, aggregating, or analyzing data from Janssen patient support programs

Also, I give permission to Janssen to receive, use, and share my Protected Health Information in order to:

- see if I qualify for, sign me up for, contact me about, and provide services relating to Janssen patient support programs, including in-home services
- manage the Janssen patient support programs
- give me educational and adherence materials, information, and resources related to my Janssen medication in connection with Janssen patient support programs
- communicate with my Healthcare Providers regarding access to, reimbursement for, and fulfillment of my Janssen medication, and to tell my Healthcare Provider that I am participating in Janssen patient support programs
- verify, assist with, and coordinate my coverage for my Janssen medication with my Insurers and Healthcare Providers
- coordinate prescription or treatment location and associated scheduling
- conduct analysis to help Janssen evaluate, create, and improve its products, services, and customer support for patients prescribed Janssen medications
- share and give access to information created by the Janssen patient support programs that may be useful for my care

I understand that my Protected Health Information may be shared by Janssen for the uses written in this Form to:

- My Insurers
- My Healthcare Providers
- Any of the persons given permission to receive and use my Protected Health Information as mentioned above
- Any individual I give permission as an additional contact

Janssen and the other data recipients listed on this Form may share information about me as permitted on this Form or if any information that specifically identifies me is removed. I understand that Janssen will use reasonable efforts to keep my information private but once my Protected Health Information is disclosed as allowed on this Form, it may no longer be protected by federal privacy laws.

I understand that I am not required to sign this Form. My choice about whether to sign will not change how my Healthcare Providers or Insurers treat me.

Janssen Patient Support Program Patient Authorization Form

If I do not sign this Form, or cancel or remove my permission later, I understand I will not be able to participate or receive assistance from Janssen's patient support programs.

I understand that pharmacies that dispense and ship my medication and service providers for the patient support programs may be paid by Janssen for their services and data. This may include payment for sharing Protected Health Information and other data in connection with these programs, as allowed on this Form.

This Form will remain in effect 10 years from the date of signature, except where state law requires a shorter time, or until I am no longer participating in any Janssen patient support programs. Information collected before that date may continue to be used for the purposes set forth in this Form.

I understand that I may cancel the permissions given by this Form at any time by letting Janssen know in writing at: Janssen CarePath, 2250 Perimeter Park Drive, Suite 300, Morrisville, NC 27560.

I can also cancel my permission by letting my Healthcare Providers and Insurers know in writing that I do not want them to share any information with Janssen. I further understand that if I cancel my permission it will not affect how Janssen uses and shares my Protected Health Information received by Janssen prior to my cancellation.

I understand I may request a copy of this Form.

Permission for communications outside	e of Janssen patient support programs:	
☐ Yes, I would like to receive communic	ations relating to my Janssen medication.	
☐ Yes, I would like to receive communic	ations relating to other Janssen products and services.	
For privacy rights and choices specific to at https://www.janssen.com/us/privac	o California residents, please see Janssen's California privad sy-policy#california	cy notice available
provided below. Message and data rat	ges. By selecting this option, I agree to receive text messa tes may apply. Message frequency varies. I understand I ar n patient support programs or to receive any other comm	m not required to provide my permission to receive text
Patient name (print):		
Patient sign here:		Date:
If the patient cannot sign, patient's legal	ly authorized representative must sign below:	
Ву:	Print Name:	Date:
(Signature of person legally authorized t	o sign for patient)	
Describe relationship to patient and authority to make medical decisions for patient:		Janssen PHARMACEUTICAL COMPANIES OF
		(lohmon flohmon